Abnormal timing of Menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study

Gregory Armstrong, John A. Whitton, Amar Gajjar, Larry E. Kun, Eric J. Chow, Marilyn Stovall, Wendy Leisenring, Leslie L. Robison, Charles A. Sklar

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

BACKGROUND: Children who receive high-dose radiotherapy to the hypothalamic-pituitary (H-P) axis may be at risk for both early and late puberty. To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited. METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche. RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9). Of the 138 survivors who received RT to the H-P axis, 20 (14.5%) had onset of menarche before age 10 years, compared with 4.3% of those who did not receive RT (OR, 3.8; 95% CI, 1.2-16.5). Age ≤4 years at the time of diagnosis was associated with an increased risk (OR, 4.0; 95% CI, 1.7-10.0) of early menarche. In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4). Doses of RT to the H-P axis >50 gray OR, 9.0; 95% CI, 2.3-59.5) and spinal RT conferred an increased risk of late menarche, as did older age (>10 years) at the time of diagnosis (OR, 3.0; 95% CI, 1.3-7.0). CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.

Original languageEnglish (US)
Pages (from-to)2562-2570
Number of pages9
JournalCancer
Volume115
Issue number11
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Central Nervous System Neoplasms
Menarche
Survivors
Radiotherapy
Odds Ratio
Confidence Intervals
Neoplasms
Siblings
Puberty
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Abnormal timing of Menarche in survivors of central nervous system tumors : A report from the Childhood Cancer Survivor Study. / Armstrong, Gregory; Whitton, John A.; Gajjar, Amar; Kun, Larry E.; Chow, Eric J.; Stovall, Marilyn; Leisenring, Wendy; Robison, Leslie L.; Sklar, Charles A.

In: Cancer, Vol. 115, No. 11, 01.06.2009, p. 2562-2570.

Research output: Contribution to journalArticle

Armstrong, G, Whitton, JA, Gajjar, A, Kun, LE, Chow, EJ, Stovall, M, Leisenring, W, Robison, LL & Sklar, CA 2009, 'Abnormal timing of Menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study', Cancer, vol. 115, no. 11, pp. 2562-2570. https://doi.org/10.1002/cncr.24294
Armstrong, Gregory ; Whitton, John A. ; Gajjar, Amar ; Kun, Larry E. ; Chow, Eric J. ; Stovall, Marilyn ; Leisenring, Wendy ; Robison, Leslie L. ; Sklar, Charles A. / Abnormal timing of Menarche in survivors of central nervous system tumors : A report from the Childhood Cancer Survivor Study. In: Cancer. 2009 ; Vol. 115, No. 11. pp. 2562-2570.
@article{ac6a9f8aa31a4172829a171d07b3163f,
title = "Abnormal timing of Menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study",
abstract = "BACKGROUND: Children who receive high-dose radiotherapy to the hypothalamic-pituitary (H-P) axis may be at risk for both early and late puberty. To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited. METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche. RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9{\%} vs 1.0{\%}) (odds ratio [OR], 14.1; 95{\%} confidence interval [95{\%} CI], 7.0-30.9). Of the 138 survivors who received RT to the H-P axis, 20 (14.5{\%}) had onset of menarche before age 10 years, compared with 4.3{\%} of those who did not receive RT (OR, 3.8; 95{\%} CI, 1.2-16.5). Age ≤4 years at the time of diagnosis was associated with an increased risk (OR, 4.0; 95{\%} CI, 1.7-10.0) of early menarche. In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6{\%} vs 1.9{\%}) (OR, 6.6; 95{\%} CI, 3.4-11.4). Doses of RT to the H-P axis >50 gray OR, 9.0; 95{\%} CI, 2.3-59.5) and spinal RT conferred an increased risk of late menarche, as did older age (>10 years) at the time of diagnosis (OR, 3.0; 95{\%} CI, 1.3-7.0). CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.",
author = "Gregory Armstrong and Whitton, {John A.} and Amar Gajjar and Kun, {Larry E.} and Chow, {Eric J.} and Marilyn Stovall and Wendy Leisenring and Robison, {Leslie L.} and Sklar, {Charles A.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1002/cncr.24294",
language = "English (US)",
volume = "115",
pages = "2562--2570",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Abnormal timing of Menarche in survivors of central nervous system tumors

T2 - A report from the Childhood Cancer Survivor Study

AU - Armstrong, Gregory

AU - Whitton, John A.

AU - Gajjar, Amar

AU - Kun, Larry E.

AU - Chow, Eric J.

AU - Stovall, Marilyn

AU - Leisenring, Wendy

AU - Robison, Leslie L.

AU - Sklar, Charles A.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - BACKGROUND: Children who receive high-dose radiotherapy to the hypothalamic-pituitary (H-P) axis may be at risk for both early and late puberty. To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited. METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche. RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9). Of the 138 survivors who received RT to the H-P axis, 20 (14.5%) had onset of menarche before age 10 years, compared with 4.3% of those who did not receive RT (OR, 3.8; 95% CI, 1.2-16.5). Age ≤4 years at the time of diagnosis was associated with an increased risk (OR, 4.0; 95% CI, 1.7-10.0) of early menarche. In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4). Doses of RT to the H-P axis >50 gray OR, 9.0; 95% CI, 2.3-59.5) and spinal RT conferred an increased risk of late menarche, as did older age (>10 years) at the time of diagnosis (OR, 3.0; 95% CI, 1.3-7.0). CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.

AB - BACKGROUND: Children who receive high-dose radiotherapy to the hypothalamic-pituitary (H-P) axis may be at risk for both early and late puberty. To the authors' knowledge, data regarding the risk of altered timing of menarche after higher dose radiotherapy (RT), as used in the treatment of central nervous system (CNS) tumors, are limited. METHODS: The authors evaluated 235 female survivors of CNS tumors, diagnosed between 1970 and 1986, and >1000 sibling controls who were participants in the Childhood Cancer Survivor Study, and provided self-reported data concerning age at menarche. RESULTS: Survivors of CNS tumors were more likely to have onset of menarche before age 10 years compared with their siblings (11.9% vs 1.0%) (odds ratio [OR], 14.1; 95% confidence interval [95% CI], 7.0-30.9). Of the 138 survivors who received RT to the H-P axis, 20 (14.5%) had onset of menarche before age 10 years, compared with 4.3% of those who did not receive RT (OR, 3.8; 95% CI, 1.2-16.5). Age ≤4 years at the time of diagnosis was associated with an increased risk (OR, 4.0; 95% CI, 1.7-10.0) of early menarche. In addition, survivors of CNS tumors were more likely than siblings to have onset of menarche after age 16 years (10.6% vs 1.9%) (OR, 6.6; 95% CI, 3.4-11.4). Doses of RT to the H-P axis >50 gray OR, 9.0; 95% CI, 2.3-59.5) and spinal RT conferred an increased risk of late menarche, as did older age (>10 years) at the time of diagnosis (OR, 3.0; 95% CI, 1.3-7.0). CONCLUSIONS: Survivors of CNS tumors are at a significantly increased risk of both early and late menarche associated with RT exposure and age at treatment.

UR - http://www.scopus.com/inward/record.url?scp=66649088601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649088601&partnerID=8YFLogxK

U2 - 10.1002/cncr.24294

DO - 10.1002/cncr.24294

M3 - Article

C2 - 19309737

AN - SCOPUS:66649088601

VL - 115

SP - 2562

EP - 2570

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -